<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003868</url>
  </required_header>
  <id_info>
    <org_study_id>1297.00</org_study_id>
    <secondary_id>FHCRC-1297.00</secondary_id>
    <secondary_id>NCI-H99-0028</secondary_id>
    <secondary_id>CDR0000067032</secondary_id>
    <nct_id>NCT00003868</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia</brief_title>
  <official_title>Radiolabeled BC8 (Anti-CD45) Antibody Combined With Cyclophosphamide and Total Body Irradiation Followed by HLA-matched Related or Unrelated Stem Cell Transplantation as Treatment for Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or&#xD;
      deliver radioactive cancer-killing substances to them without harming normal cells. Drugs&#xD;
      used in chemotherapy work in different ways to stop cancer cells from dividing so they stop&#xD;
      growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Donor stem&#xD;
      cell transplantation may be able to replace immune cells that were destroyed by radiolabeled&#xD;
      monoclonal antibody therapy, chemotherapy and radiation therapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining radiolabeled monoclonal&#xD;
      antibody with cyclophosphamide and total-body irradiation followed by donor stem cell&#xD;
      transplantation in treating patients who have advanced acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy, in terms of overall survival and disease-free survival, and&#xD;
           toxicity of cyclophosphamide and total body irradiation in patients with acute myeloid&#xD;
           leukemia beyond first remission receiving HLA-matched related or unrelated hematopoietic&#xD;
           stem cell transplantation.&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of iodine I 131 monoclonal antibody BC8 (I131&#xD;
           MOAB BC8) in these patients.&#xD;
&#xD;
        -  Estimate the MTD of radiation delivered by I 131 MOAB BC8 to marrow of these patients&#xD;
           and assess the effects on growth of marrow stroma in vitro.&#xD;
&#xD;
      OUTLINE: This is radiation dose-escalation study. Patients are stratified according to&#xD;
      available donor (related vs unrelated).&#xD;
&#xD;
      Patients receive a biodistribution dose of iodine I 131 monoclonal antibody BC8 (I131 MOAB&#xD;
      BC8) IV, then a therapeutic dose of I131 MOAB BC8 IV 6-14 days later (day -12). Patients&#xD;
      undergo total body irradiation twice daily on days -6 to -4. Patients receive&#xD;
      cyclophosphamide IV on days -3 and -2. Bone marrow cells (or peripheral blood stem cells) are&#xD;
      infused on day 0.&#xD;
&#xD;
      Patients with CNS leukemic involvement receive intrathecal methotrexate twice before the&#xD;
      transplantation then every other week for 8 weeks beginning on day 32. These patients also&#xD;
      receive cranial irradiation beginning on day 32.&#xD;
&#xD;
      Cohorts of 4 patients each receive escalating doses of iodine I 131 attached to a standard&#xD;
      dose of monoclonal antibody BC8 until the maximum tolerated dose (MTD) is determined. The MTD&#xD;
      is defined as the radiation dose preceding that at which 2 of up to 6 patients experience&#xD;
      graft failure.&#xD;
&#xD;
      Patients are followed at 6, 9, and 12 months, every 6 months for 1 year, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients (20 per stratum) will be accrued for this study&#xD;
      within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody BC8</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) beyond first remission OR with primary refractory&#xD;
                  disease&#xD;
&#xD;
               -  AML that has transformed from myelodysplastic syndromes, if induction&#xD;
                  chemotherapy not recommended&#xD;
&#xD;
          -  Documented CD45 expression in patients with relapsed disease&#xD;
&#xD;
               -  Not needed for patients in remission&#xD;
&#xD;
          -  Circulating blast count less than 10,000/mm^3 (may be controlled with hydroxyurea or&#xD;
             similar agent)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  2 to 55&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 60 days&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL (unless bilirubin is determined by the gastroenterology&#xD;
             service to be predominantly unconjugated [indirect] as the result of possible&#xD;
             hemolysis)&#xD;
&#xD;
          -  AST less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL OR less than 1.5 times ULN for age&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No major infection&#xD;
&#xD;
          -  No circulating antibodies to mouse immunoglobulins&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Able to tolerate diagnostic or therapeutic procedures (e.g., radiation isolation)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No radiotherapy to maximum tolerated levels to any normal organ&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eneida Nemecek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>August 20, 2010</last_update_submitted>
  <last_update_submitted_qc>August 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2010</last_update_posted>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

